Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …

Infection remains the leading cause of morbidity and mortality in patients with multiple
myeloma because of the cumulative effect of disease, treatment, and host-related factors …

Background Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …

Background Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven
efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M …

Background As lenalidomide becomes increasingly established for upfront treatment of
multiple myeloma, patients refractory to this drug represent a population with an unmet …

Abstract The European Conference on Infections in Leukaemia (ECIL) updated its
guidelines on antifungal prophylaxis for adults using the grading system of IDSA. The …

Background The adjuvanted recombinant zoster vaccine (Shingrix) can prevent herpes
zoster in older adults and autologous haemopoietic stem cell transplant recipients. We …

Infections are a major cause of morbidity and mortality in patients with multiple myeloma. To
estimate the risk of bacterial and viral infections in multiple myeloma patients, we used …

Antibody deficiency or hypogammaglobulinemia can have primary or secondary etiologies.
Primary antibody deficiency (PAD) is the result of intrinsic genetic defects, whereas …

Background The impact of coronavirus disease 2019 (COVID‐19) in haematological
patients (HP) has not been comprehensively reported. Methods We analysed 39 patients …